XML 92 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 32 Months Ended
Apr. 02, 2018
May 05, 2016
USD ($)
$ / shares
shares
Apr. 30, 2018
USD ($)
Target
$ / shares
shares
Feb. 28, 2018
USD ($)
May 31, 2016
USD ($)
Program
$ / shares
shares
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Equity investment aggregate purchase price                           $ 60,000,000 $ 93,509,000 $ 30,000,000  
Collaboration and license agreement, deferred revenue current           $ 100,945,000       $ 1,275,000       100,945,000 1,275,000   $ 100,945,000
Proceeds from issuance of ordinary shares, net of offering costs                           60,000,000 93,509,000 30,000,000  
Collaboration revenue recognized           3,620,000 $ 4,493,000 $ 4,879,000 $ 1,422,000 $ 1,098,000 $ 1,315,000 $ 1,097,000 $ 383,000 $ 14,414,000 3,893,000 1,092,000  
Pfizer Inc. [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Number of research programs, counterparty nomination | Program         5                        
Research term, description                           Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during a four-year research term. During the research term, the Company is responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates. At that stage, Pfizer may elect to license any of these Pfizer Programs exclusively and obtain exclusive rights to undertake the clinical development of the resulting clinical candidates into products and the potential commercialization of any such products thereafter.      
Collaboration agreement, additional period after research program   2 years                              
Up-front consideration received   $ 10,000,000                              
Revenue recognized                           $ 4,900,000 $ 3,900,000 $ 1,100,000 9,900,000
Collaboration and license agreement, deferred revenue           8,700,000               8,700,000     8,700,000
Collaboration and license agreement, deferred revenue current           6,800,000               $ 6,800,000     6,800,000
Remaining research term                           16 months      
Takeda [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Up-front consideration received     $ 110,000,000                            
Research, License and Option Agreement [Member] | Pfizer Inc. [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payment under collaboration agreement         $ 10,000,000                        
Collaboration agreement refundable         $ 0                        
Shares issued under equity agreement | shares   1,875,000     1,875,000                        
Equity investment aggregate purchase price   $ 30,000,000     $ 30,000,000                        
Purchase price per share | $ / shares   $ 16.00     $ 16.00                        
Collaborative agreement research term         4 years                        
Collaboration agreement termination period   90 days                              
Collaboration And License Agreement [Member] | Category One Programs [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Percentage of global costs and potential profits sharing ratio     50.00%                            
Collaboration And License Agreement [Member] | Takeda [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Upfront payment under collaboration agreement     $ 110,000,000                            
Collaboration agreement termination period 180 days                                
Collaboration and license agreement, deferred revenue           160,400,000               $ 160,400,000     160,400,000
Collaboration and license agreement, deferred revenue current           94,100,000               94,100,000     94,100,000
Collaboration and license agreement month and year     2018-02                            
Fund receivable for research and preclinical activities     $ 60,000,000                            
Research term under collaboration and license agreement     4 years                            
Collaboration agreement commencement date Apr. 02, 2018                                
Collaboration revenue recognized                           9,600,000      
Collaboration and license agreement, accounts receivable           60,000,000               60,000,000     60,000,000
Collaboration and license agreement, accounts receivable current           $ 10,000,000               $ 10,000,000     $ 10,000,000
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Percentage of global costs and potential profits sharing ratio     50.00%                            
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Fund receivable for research and preclinical activities     $ 60,000,000                            
Research term under collaboration and license agreement     4 years                            
Maximum targets for preclinical programs | Target     6                            
Option to reach maximum targets for preclinical programs                           any one time      
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Collaboration agreement, committed cash       $ 230,000,000                          
Collaboration and Share Purchase Agreements [Member] | Takeda [Member]                                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                  
Shares issued under equity agreement | shares     1,096,892                            
Equity investment aggregate purchase price     $ 60,000,000                            
Purchase price per share | $ / shares     $ 54.70                            
Proceeds from issuance of ordinary shares, net of offering costs     $ 60,000,000                            
Equity investment agreement official closure month and year     2018-04